AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03659266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic walking rehabilitation by Lokomat®
Description: Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
Study NCT03659266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional walking rehabilitation
Description: 5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
Study NCT00818610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta lactam (amoxicillin / clav. acid OR cefuroxime)
Description: 1.2 g 4x/d OR 1.5 g 3x/d IV
Study NCT00818610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
Description: 1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
Study NCT03028311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography
Description: Undergo angiography
Study NCT03028311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: Undergo SPECT-CT
Study NCT03028311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Planar Imaging
Description: Undergo planar imaging
Study NCT03028311 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radioembolization
Description: Undergo radioembolization
Study NCT03028311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT-CT
Study NCT03028311 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Given via arterial catheter
Study NCT04810143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitra Microsampler
Description: an FDA Class I medical device for direct specimen collection of blood or other biological fluids
Study NCT03028311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yttrium Y 90 Resin Microspheres
Description: Given via arterial catheter
Study NCT02647125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huachansu
Description: Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
Study NCT02647125 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: thoracic radiation
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study NCT02647125 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study NCT03290937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT03290937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03290937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study NCT02822313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987518)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76_V27-006)
Study NCT04374851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polaris miniRITE BTE
Description: The Polaris device is programmed with computer software to match the Hearing loss of the participant.
Study NCT03290937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mammogram
Description: Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mammogram
Description: Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT03672331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tomosynthesis
Description: As required according to the national/regional guidelines or personalised schedule according to risk assessment
Study NCT05025059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in coaching sessions
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform walking exercise
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform strength exercises
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Maintain exercise log
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear fitness tracker
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT05025059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00780195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
Study NCT00780195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
Study NCT00780195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
Study NCT00780195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: 2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
Study NCT03740048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
Study NCT03740048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
Study NCT03740048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Product
Description: Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
Study NCT02296164 — intervention group
Intervention type: DRUG
Intervention: Valchlor
Description: Valchlor gel 0.016%
Study NCT02495428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Method
Study NCT03549923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous CRRT
Description: The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
Study NCT03549923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional-indication CRRT
Description: The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
Study NCT03549923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
Study NCT03549923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
Study NCT03327493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological
Description: We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)
Study NCT02799836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blindfold
Description: Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
Study NCT02268890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
Study NCT04595071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Activated Prosthetic Interface (VAPI) Controller
Description: A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
Study NCT02873871 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standardized compressive dressing
Description: Standardized compressive dressing
Study NCT02873871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis with TerumoBand®
Description: Hemostasis with TerumoBand®
Study NCT01672645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIC7-001
Description: Intramuscular, multiple dose
Study NCT01672645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIC7-003
Description: Intramuscular, multiple dose
Study NCT01672645 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9% sodium chloride)
Study NCT04559568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3522348
Description: Administered orally.
Study NCT04559568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04559568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally to some participants.
Study NCT04559568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally to some participants.
Study NCT04374851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viron miniRiTE BTE
Description: The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
Study NCT02784951 — intervention group
Intervention type: DRUG
Intervention: Red blood cells (0Rh D-neg)
Description: Fresh produced RBC
Study NCT02784951 — intervention group
Intervention type: DRUG
Intervention: Whole blood (O Rh D-neg K-neg)
Description: Fresh produced WB
Study NCT02784951 — intervention group
Intervention type: DRUG
Intervention: Freeze dried plasma (LyoPlas)
Description: (LyoPlas N-w (German Red Cross)
Study NCT02122016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCare
Description: Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
Study NCT02122016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional weaning protocol
Description: A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
Study NCT04175223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
Study NCT05708911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal exerciser
Description: Pharyngo-esophageal manometry during lateral fluoroscopy
Study NCT01559753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Study NCT04877626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemeter plus lumefantrina vs artesunato plus amodiquina
Description: Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
Study NCT01161940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
Study NCT01161940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axid
Description: Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Study NCT03210948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTE-guided EUS-FNA
Description: Fine needle aspiration with 25 gauge needle under RTE-guidance
Study NCT03210948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EUS-FNA
Description: Fine needle aspiration with no RTE guidance
Study NCT01384175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesia
Description: Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
Study NCT01384175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural infusion
Description: Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
Study NCT01384175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled epidural analgesia
Description: Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
Study NCT02473081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention
Description: Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
Study NCT02473081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care was given by their family physicians.
Study NCT02473081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care was given by their family physicians.
Study NCT01667900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Study NCT01559753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compare 8 to15 days of antibiotic treatment
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Study NCT01559753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compare 8 to15 days of antibiotic treatment
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Study NCT01934361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
Study NCT01934361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
Study NCT01934361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
Study NCT01934361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lomustine
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
Study NCT01934361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
Study NCT01667900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Study NCT01667900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Study NCT03563339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-POD
Description: . P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
Study NCT04031599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop system
Description: Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
Study NCT04031599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Tandem Diabetes Care
Study NCT04031599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Dexcom G6
Study NCT04031599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart or Lispro
Description: Aspart or lispro will be infused with the infusion pump